Article Versions Notes

Gentinetta T, Belcher JD, Brügger-Verdon V, Adam J, Ruthsatz T, Bain J, Schu D, Ventrici L, Edler M, Lioe H, et al. Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence. Journal of Clinical Medicine. 2022; 11(3):630. https://doi.org/10.3390/jcm11030630

Gentinetta, Thomas, John D. Belcher, Valérie Brügger-Verdon, Jacqueline Adam, Tanja Ruthsatz, Joseph Bain, Daniel Schu, Lisa Ventrici, Monika Edler, Hadi Lioe, and et al. 2022. "Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence" Journal of Clinical Medicine 11, no. 3: 630. https://doi.org/10.3390/jcm11030630

Gentinetta, T., Belcher, J. D., Brügger-Verdon, V., Adam, J., Ruthsatz, T., Bain, J., Schu, D., Ventrici, L., Edler, M., Lioe, H., Patel, K., Chen, C., Nguyen, J., Abdulla, F., Zhang, P., Wassmer, A., Jain, M., Mischnik, M., Pelzing, M., ... Höbarth, G. (2022). Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence. Journal of Clinical Medicine, 11(3), 630. https://doi.org/10.3390/jcm11030630